Biopharmaceutical Practice

The Biopharmaceutical practice at Kineticos assists growth-oriented pharmaceutical and biotech companies realize their commercial potential at the corporate, portfolio and product levels. Our consulting team has a depth of expertise across functional areas and therapeutic areas, established through decades of work in consulting or in industry. Overall the practice has a strong commitment to client satisfaction and a proven ability to deliver results through practical solutions.

The Biopharmaceutical Practice at Kineticos supports clients across three service areas including:

Corporate Strategy & Development

  • Business Model Design
  • Portfolio Strategy
  • Geographic Market Entry Strategy
  • Opportunity Assessment
  • In- and Out- Licensing
  • Private Financing

Medical Affairs Strategy

  • Medical Affairs Strategic Planning & Operations
  • MSL Architecture, Management and Support
  • Real World Evidence/Registry Study

Commercial Strategy

  • New Product Planning
  • Strategic Launch Planning
  • Post-Marketing Strategy and Planning
  • Lifecycle Management
  • Marketing Excellence


  • Regulatory Strategy
  • Product Development
  • Regulatory Operations & Submissions Management

Click the Tabs Below for Biopharmaceutical Practice Case Studies, White Papers and Articles, and Blog


Case Studies
  • Portfolio Prioritization – Oncology

    Situation: A publicly traded Oncology company with 3 technology platforms and limited resources was in need of narrowing their focus. 


    Read this Case Study

  • Oncology Commercial Assessment – Melanoma

    Situation: A clinical-stage oncology company with a potentially ground-breaking technology requested Kineticos to help determine which tumor type(s) had the


    Read this Case Study

  • Business Development & Licensing

    Situation: An innovative oncology diagnostics company retained Kineticos to assist in developing their pitch deck, as well as developing and


    Read this Case Study

  • Product Search

    Situation: A drug delivery technology company identified an opportunity to generate additional revenue by acquiring products to further develop and


    Read this Case Study

  • Commercial Assessment

    Situation: A mid-sized biotech company evaluating their Phase II Metabolic asset requested that Kineticos provide a commercial and financial assessment


    Read this Case Study

  • Business Development and Licensing

    Situation: A publicly traded pharmaceutical company seeking a strategic partner for their IND-ready asset was in need of support with


    Read this Case Study

  • Are Checkpoint Inhibitors Impacting How We Cure Disease?

    Throughout September and October, we have been discussing Precision Medicine and it’s impact on various segments of the life sciences.


    Read this Article

  • Oncology, Rare Diseases, and Regenerative Medicine: Where does Companion Diagnostics fit in each

    Moving on from our Precision Medicine in Neurosciences, Kineticos’ Founder and CEO, Shailesh Maingi, talks with a diagnostics expert on


    Read this Article

  • Partnerships: Is Sharing Better for Precision Medicine in Neuroscience?

    Closing out our Precision Medicine in Neurosciences discussion, Nik and Jason discuss how various partnerships can impact the success of


    Read this Article

  • Biomarkers, Partnerships, and Companion Diagnostics: How will they impact the approval of Neuroscience Drugs?

    Continuing our Precision Medicine in Neuroscience discussion, Jason Kralic and Nik Tezapsidis discuss how biomarkers and partnerships will drive precision


    Read this Article

  • 8 Key Principles to Building a Board of Directors

    There are too many great ideas that never reach the surface in our industry and that’s where Kineticos’ newest family


    Read this Article

  • The FDA’s Shift from Gate Keeper to Enabler

    Most of us were shocked when Scott Gottlieb stepped down from his duties as the FDA Commissioner. He is largely


    Read this Article

  • Growth by Acquisition in Life Sciences: Do You Have a Plan?

    Article Preview As the life sciences landscape continually changes, growth by acquisition has become increasingly common. Recent deals, such as


    Read this Blog Post

  • R&D Revolutionaries: Why the Actavis/Allergan Deal Takes a Stand for Biopharma’s True Roots in Innovation

    James Forte of Kineticos takes an in-depth look at the recent Actavis/Allergan deal including the role R&D innovation played in shaping the deal’s outcome. Let’s be candid. It’s been awhile since any biopharma company was able to claim R&D as a core competency with a straight face. Biopharma’s R&D efforts have long been challenged, and rightly so given its output, but the Actavis/Allergan deal shows that the right investment in R&D can revolutionize a business. Could efficient R&D be the new definition of innovation?


    Read this Blog Post

  • Merck KGaA and Bayer Choose Opposite Strategies

    Article Preview Europe’s two largest chemical and drug conglomerates are changing course in starkly opposite ways. As reported in recent


    Read this Blog Post

  • Foundation Medicine and Clovis Expand Partnership

    Article Preview In April 2014, Foundation Medicine and Clovis Oncology announced the expansion of their partnership by developing a companion


    Read this Blog Post

  • Role of Companion Diagnostics in Immuno-oncology Race Unfolding

    Article Preview Important oncology events, including ASCO and ESMO, have recently displayed the fruits of the huge investment drug companies


    Read this Blog Post

  • Bayer to Divest Plastics Unit to Improve R&D, Acquisition Capacity

    Article Preview As reported by Bloomberg and the Wall Street Journal, Bayer is expected to announce plans to sell its


    Read this Blog Post

Subscribe to our internal think tank, Kineticos Research Institute